Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with BRAF/MEK-inhibitors evidenced by an algorithm-defined pyrexia score

Hannah Schaefer, View ORCID ProfileAlbert Rübben, André Esser, View ORCID ProfileArturo Araujo, Oana-Diana Persa, Marike Leijs
doi: https://doi.org/10.1101/2022.03.29.22272913
Hannah Schaefer
1Department of Dermatology, RWTH Aachen University Hospital, Aachen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert Rübben
1Department of Dermatology, RWTH Aachen University Hospital, Aachen, Germany
2Department of Dermatology St. Nikolaus Hospital, Eupen, Belgium
6Center for Integrated Oncology, CIO ABCD (Aachen, Bonn, Cologne, Düsseldorf)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Albert Rübben
  • For correspondence: albert.ruebben@post.rwth-aachen.de
André Esser
3Department of Occupational, Social and Environmental Medicine, RWTH Aachen University Hospital, Aachen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arturo Araujo
4University of Roehampton, Department of Media, Culture and Language London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Arturo Araujo
Oana-Diana Persa
5Department of Dermatology and Venereology, University Hospital Cologne, University of Cologne, Cologne, Germany
6Center for Integrated Oncology, CIO ABCD (Aachen, Bonn, Cologne, Düsseldorf)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marike Leijs
1Department of Dermatology, RWTH Aachen University Hospital, Aachen, Germany
2Department of Dermatology St. Nikolaus Hospital, Eupen, Belgium
6Center for Integrated Oncology, CIO ABCD (Aachen, Bonn, Cologne, Düsseldorf)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Pyrexia is a frequent adverse event of BRAF/MEK-inhibitor combination therapy in patients with metastasized malignant melanoma (MM). The study’s objective was to identify laboratory changes which might correlate with the appearance of pyrexia. Initially, data of 38 MM (14 with pyrexia) patients treated with dabrafenib plus trametinib were analysed retrospectively. Graphical visualization of time series of laboratory values suggested that a rise in C-reactive-protein, in parallel with a fall of leukocytes and thrombocytes, were indicative of pyrexia. Additionally, statistical analysis showed a significant correlation between lactate dehydrogenase (LDH) and pyrexia. An algorithm based on these observations was designed using a deductive approach in order to calculate a pyrexia score (PS) for each laboratory assessment in treated patients. A second independent data set with 28 MM patients (8 with pyrexia) was used for the validation of the algorithm. PS based on the four parameters CRP, LDH, leukocyte and thrombocyte numbers, were statistically significantly higher in pyrexia patients, differentiated between groups (F=20,8; p=<0,0001) and showed a significant predictive value for the development of pyrexia (F=6,24; p=0,013). We provide first evidence that pyrexia in patients treated with BRAF/MEK-blockade can be identified and predicted by an algorithm that calculates a score.

SUMMARY STATEMENT Pyrexia is a severe side effect of BRAF/MEK-inhibitor therapy of malignant melanoma. An algorithm based on the four laboratory values, leukocyte and thrombocyte counts, CRP and LDH, was designed for detecting pyrexia. The used heuristic approach might serve as a blueprint for analysing unevenly sampled or even incomplete clinical data.

Competing Interest Statement

The authors declare no conflict of interest. A.R. has received travel grants and consulting remunerations from Roche, MSD, BMS, Amgen and Novartis as well as a research grant from Novartis unrelated to the presented study.

Funding Statement

This study did not receive any funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Ethics Committee of the University Hospital Aachen, RWTH Aachen University, gave ethical approval for this work(ethic vote 257/19). Due to the purely retrospective nature of the performed data analysis, patient informed consent was not deemed necessary by the Ethics Commitee.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* These authors share last authorship

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 02, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with BRAF/MEK-inhibitors evidenced by an algorithm-defined pyrexia score
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with BRAF/MEK-inhibitors evidenced by an algorithm-defined pyrexia score
Hannah Schaefer, Albert Rübben, André Esser, Arturo Araujo, Oana-Diana Persa, Marike Leijs
medRxiv 2022.03.29.22272913; doi: https://doi.org/10.1101/2022.03.29.22272913
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with BRAF/MEK-inhibitors evidenced by an algorithm-defined pyrexia score
Hannah Schaefer, Albert Rübben, André Esser, Arturo Araujo, Oana-Diana Persa, Marike Leijs
medRxiv 2022.03.29.22272913; doi: https://doi.org/10.1101/2022.03.29.22272913

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (579)
  • Anesthesia (141)
  • Cardiovascular Medicine (1955)
  • Dentistry and Oral Medicine (253)
  • Dermatology (186)
  • Emergency Medicine (333)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (702)
  • Epidemiology (11118)
  • Forensic Medicine (8)
  • Gastroenterology (629)
  • Genetic and Genomic Medicine (3192)
  • Geriatric Medicine (309)
  • Health Economics (565)
  • Health Informatics (2048)
  • Health Policy (864)
  • Health Systems and Quality Improvement (788)
  • Hematology (310)
  • HIV/AIDS (684)
  • Infectious Diseases (except HIV/AIDS) (12738)
  • Intensive Care and Critical Care Medicine (708)
  • Medical Education (318)
  • Medical Ethics (92)
  • Nephrology (336)
  • Neurology (2999)
  • Nursing (165)
  • Nutrition (465)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1560)
  • Ophthalmology (478)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (914)
  • Pharmacology and Therapeutics (382)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2795)
  • Public and Global Health (5609)
  • Radiology and Imaging (1100)
  • Rehabilitation Medicine and Physical Therapy (635)
  • Respiratory Medicine (764)
  • Rheumatology (340)
  • Sexual and Reproductive Health (314)
  • Sports Medicine (289)
  • Surgery (347)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (133)